Abstract
Background and Aims: HeFH disease severity is linked to the causative mutation type. Important mutations in HeFH include those with two variants; double heterozygous (DH) and compound heterozygous (CH), which are frequently similar phenotypically to HoFH; and functional mutations in LDLR (negative, defective and unknown). This analysis explored the efficacy of inclisiran in patients with these genotypes along with the genotypes examined previously.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
